Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-22-003074
Filing Date
2022-08-12
Accepted
2022-08-12 07:30:40
Documents
30
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2228232.htm   iXBRL 10-Q 777014
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 15586
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 15496
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 6451
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 6232
  Complete submission text file 0001178913-22-003074.txt   2303326

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cmmb-20220630.xsd EX-101.SCH 19998
7 XBRL CALCULATION FILE cmmb-20220630_cal.xml EX-101.CAL 24953
8 XBRL DEFINITION FILE cmmb-20220630_def.xml EX-101.DEF 48569
9 XBRL LABEL FILE cmmb-20220630_lab.xml EX-101.LAB 212353
10 XBRL PRESENTATION FILE cmmb-20220630_pre.xml EX-101.PRE 98985
24 EXTRACTED XBRL INSTANCE DOCUMENT zk2228232_htm.xml XML 168746
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38807 | Film No.: 221157820
SIC: 2834 Pharmaceutical Preparations